Education
About Us
Working with TipRanks
Follow Us
DMK Pharmaceuticals (DMKPQ)
OTHER OTC:DMKPQ
Total Valuation
DMK Pharmaceuticals has a market cap or net worth of $1.01K. The enterprise value is $1.83M.
Market Cap$1.01K
Enterprise Value$1.83M
Share Statistics
DMK Pharmaceuticals has 10,102,050 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding10,102,050
Owned by Insiders―
Owned by Institutions<0.01%
Financial Efficiency
DMK Pharmaceuticals’s return on equity (ROE) is 40.69 and return on invested capital (ROIC) is 20463.87%.
Return on Equity (ROE)40.69
Return on Assets (ROA)-2.42
Return on Invested Capital (ROIC)20463.87%
Return on Capital Employed (ROCE)53.89
Revenue Per Employee432.37K
Profits Per Employee-2.38M
Employee Count11
Asset Turnover0.44
Inventory Turnover6.18
Valuation Ratios
The current PE Ratio of DMK Pharmaceuticals is -0.10. DMK Pharmaceuticals’s PEG ratio is <0.01.
PE Ratio-0.10
PS Ratio0.00
PB Ratio-3.95
Price to Fair Value-3.95
Price to FCF-0.10
Price to Operating Cash Flow-0.10
PEG Ratio<0.01
Income Statement
In the last 12 months, DMK Pharmaceuticals had revenue of 4.76M and earned -26.48M in profits. Earnings per share was -12.37.
Revenue4.76M
Gross Profit-2.90M
Operating Income-25.06M
Pretax Income-26.20M
Net Income-26.48M
EBITDA-23.58M
Earnings Per Share (EPS)-12.37
Cash Flow
In the last 12 months, operating cash flow was -9.38M and capital expenditures -91.49K, giving a free cash flow of -9.47M billion.
Operating Cash Flow-9.38M
Free Cash Flow-9.47M
Free Cash Flow per Share-0.94
Dividends & Yields
DMK Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-81.67
52-Week Price Change-66.67%
50-Day Moving Average―
200-Day Moving Average―
Relative Strength Index (RSI)―
Average Volume (3m)10.22K
Important Dates
DMK Pharmaceuticals upcoming earnings date is Nov 12, 2024, TBA (Confirmed).
Last Earnings DateAug 8, 2024
Next Earnings DateNov 12, 2024
Ex-Dividend Date―
Financial Position
DMK Pharmaceuticals as a current ratio of 0.81, with Debt / Equity ratio of -52.64%
Current Ratio0.81
Quick Ratio0.70
Debt to Market Cap0.00
Net Debt to EBITDA0.03
Interest Coverage Ratio0.00
Taxes
In the past 12 months, DMK Pharmaceuticals has paid 2.00K in taxes.
Income Tax2.00K
Effective Tax Rate>-0.01
Enterprise Valuation
DMK Pharmaceuticals EV to EBITDA ratio is -0.08, with an EV/FCF ratio of -0.07.
EV to Sales0.38
EV to EBITDA-0.08
EV to Free Cash Flow-0.07
EV to Operating Cash Flow-0.07
Balance Sheet
DMK Pharmaceuticals has $6.66M in cash and marketable securities with $63.21K in debt, giving a net cash position of -$6.60M billion.
Cash & Marketable Securities$6.66M
Total Debt$63.21K
Net Cash-$6.60M
Net Cash Per Share-$0.65
Tangible Book Value Per Share-$0.30
Margins
Gross margin is -60.93%, with operating margin of -526.88%, and net profit margin of -556.72%.
Gross Margin-60.93%
Operating Margin-526.88%
Pretax Margin-550.82%
Net Profit Margin-556.72%
EBITDA Margin-495.69%
EBIT Margin-526.88%
Analyst Forecast
The average price target for DMK Pharmaceuticals is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―